Redx Pharma reports on zamaporvint cancer treatment trials
Redx Pharma has announced data from all Phase II clinical trial modules of zamaporvint (RXC004), a potent, selective, orally-active Porcupine inhibitor in development for Wnt-ligand dependent, hard-to-treat gastrointestinal (GI) cancers. These data, presented at the European Society for Medical Oncology Gastrointestinal Cancers (ESMO GI) Congress, were from… Read More